FDA studying physical attributes of generic drugs; Drug-device partnership to treat brain cancer debuts;

> The FDA is studying how the color, shape or size of a generic drug affects patient adherence, as it seeks to improve patient compliance with labeling and doctors' orders. More

> DNAtrix will use its Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, its candidate for treating a form of aggressive brain cancer known as glioblastoma. More